449 related articles for article (PubMed ID: 29058166)
1. Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.
Kaminski TW; Pawlak K; Karbowska M; Mysliwiec M; Grzegorzewski W; Kuna J; Pawlak D
Int Urol Nephrol; 2018 Jan; 50(1):127-135. PubMed ID: 29058166
[TBL] [Abstract][Full Text] [Related]
2. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
Pawlak K; Buraczewska-Buczko A; Mysliwiec M; Pawlak D
Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis?
Pawlak K; Ulazka B; Mysliwiec M; Pawlak D
Transl Res; 2012 Nov; 160(5):346-54. PubMed ID: 22683425
[TBL] [Abstract][Full Text] [Related]
4. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
[TBL] [Abstract][Full Text] [Related]
5. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.
Kamiński TW; Pawlak K; Karbowska M; Myśliwiec M; Pawlak D
BMC Nephrol; 2017 Jan; 18(1):35. PubMed ID: 28122514
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2006; 117(5):517-22. PubMed ID: 15964061
[TBL] [Abstract][Full Text] [Related]
8. Longitudinally Measured Fibrinolysis Factors are Strong Predictors of Clinical Outcome in Patients with Chronic Heart Failure: The Bio-SHiFT Study.
van den Berg VJ; Bouwens E; Umans VAWM; de Maat M; Manintveld OC; Caliskan K; Constantinescu AA; Mouthaan H; Cornel JH; Baart S; Akkerhuis KM; Boersma E; Kardys I
Thromb Haemost; 2019 Dec; 119(12):1947-1955. PubMed ID: 31659734
[TBL] [Abstract][Full Text] [Related]
9. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
[TBL] [Abstract][Full Text] [Related]
10. The fibrinolytic system: A new target for treatment of depression with psychedelics.
Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
[TBL] [Abstract][Full Text] [Related]
11. Cross-talk between inflammation,coagulation/fibrinolysis and vascular access in hemodialysis patients.
Costa E; Rocha S; Rocha-Pereira P; Castro E; Reis F; Teixeira F; Miranda V; Do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
J Vasc Access; 2008; 9(4):248-53. PubMed ID: 19085894
[TBL] [Abstract][Full Text] [Related]
12. The effect of chronic allograft rejection on plasma regulators of fibrinolysis.
Perkowska A; Elhasade A; Durlik M; Placha G; Gałazka Z; Lao M; Gaciong Z
Ann Transplant; 2002; 7(1):44-51. PubMed ID: 12221903
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
14. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients.
Cardenas JC; Matijevic N; Baer LA; Holcomb JB; Cotton BA; Wade CE
Shock; 2014 Jun; 41(6):514-21. PubMed ID: 24667610
[TBL] [Abstract][Full Text] [Related]
15. Increased fibrin formation and impaired fibrinolytic capacity in severe chronic kidney disease.
Mörtberg J; Blombäck M; Wallén Å; He S; Jacobson SH; Spaak J
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):401-7. PubMed ID: 26650459
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Ho CH; Yuan CC; Liu SM
Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
[TBL] [Abstract][Full Text] [Related]
17. Hemostasis, platelet function and serotonin in acute and chronic renal failure.
Malyszko J; Malyszko JS; Pawlak D; Pawlak K; Buczko W; Mysliwiec M
Thromb Res; 1996 Sep; 83(5):351-61. PubMed ID: 8873344
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
Pawlak K; Pawlak D; Myśliwiec M
Thromb Res; 2008; 121(4):543-8. PubMed ID: 17706748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
